Vardenafil provides reliable efficacy over time in men with erectile dysfunction

Montorsi, Francesco; Hellstrom, Wayne J.G.; Valiquette, Luc; Bastuba, Martin; Collins, Owen; Taylor, Terry; Thibonnier, Marc; Homering, Martin; Eardley, Ian

doi:10.1016/j.urology.2004.07.032

Cited by 30 publications

(20 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers have evaluated first‐dose successful responses to PDE5 inhibitors as a study end‐point (110–113). In the recent Reliability of Vardenafil for Erectile Dysfunction (RELY)‐II trial, 70–81% first‐dose treatment success was reported with high‐dose (20 mg), on‐demand vardenafil therapy in patients with numerous comorbidities (Figure 5; 114).…”

Section: Resultsmentioning

confidence: 99%

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction

Sadovsky

Brock

Gutkin³

et al. 2009

International Journal of Clinical Practice

View full text Add to dashboard Cite

Despite the marked adverse impacts of erectile dysfunction (ED) on quality of life and well-being, many patients (and/or their partners) do not seek medical attention for this problem, do not receive treatment or discontinue such treatment even when it has effectively restored erectile responses to sexual stimulation. Phosphodiesterase type 5 (PDE5) inhibitors are considered first-line therapies for men with ED. To help physicians maximise the likelihood of treatment success with these agents, we conducted an English-language PubMed search of articles involving approved PDE5 inhibitors dating from 1 January 1998 (the year in which sildenafil citrate was introduced), through 31 August 2008. In addition to sildenafil, tadalafil and vardenafil, search terms included ‘adhere*’, ‘couple*’, ‘effect*’, ‘effic*’, ‘partner*’, ‘satisf*’, ‘succe*’ and ‘treatment outcome.’ Based on our analysis, physician activities to promote favourable treatment outcomes may be captured under the mnemonic ‘EPOCH’: (i) Evaluating and educating patients and partners to ensure realistic expectations of therapy; (ii) Prescribing a treatment individualised to the couple’s lifestyle needs and other preferences; (iii) Optimising treatment outcomes by scheduling follow-up visits with the patient to ‘fine-tune’ dosages and revisit key educational messages; (iv) Controlling comorbidities via lifestyle counselling, medications and/or referrals and (v) Helping patients and their partners to meet their health and psychosocial needs, potentially referring them to a specialist for other forms of therapy if they are not satisfied with PDE5 inhibitors.

show abstract

Section: Resultsmentioning

confidence: 99%

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction

Sadovsky

Brock

Gutkin³

et al. 2009

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…118 Similar response rates were seen with vardenafil (Levitra ® , Bayer Pharmaceuticals, Westhaven, CT) and tadalafil (Cialis ® , Lily/ Icos, Indianapolis, IN). [119][120][121][122][123] Potential adverse effects with all agents in this class include headache, flushing, transient hypotension, and nasal congestion secondary to vasodilation. [123][124][125] Visual changes due to non-arteritic anterior ischemic optic neuropathy are also described.…”

Section: Treatment Of Edmentioning

confidence: 99%

A Review of Hypogonadism and Erectile Dysfunction Among HIV-Infected Men During the Pre- and Post-HAART Eras: Diagnosis, Pathogenesis, and Management

Crum

Furtek

Olson

et al. 2005

AIDS Patient Care and STDs

View full text Add to dashboard Cite

Hypogonadism and erectile dysfunction (ED) appear to be more common among men infected with HIV compared to age-matched men within the general U.S. population. HIV providers should consider these conditions and utilize standardized evaluation and diagnostic criteria. Treatment of both hypogonadism and ED increases sexual function and quality of life; testosterone supplementation in the setting of hypogonadism may also improve lean body mass, mental status, and anemia. We review the epidemiology, diagnosis, pathogenesis, and treatment options of both hypogonadism and ED among HIV-infected men.

show abstract

“…4 An important factor in the management of ED is the reliability of the medication over time. 5,6 Reliability refers to the consistent response to an ED medication, and has also been referred to as 'maintenance of success' in the literature. 5 Reliable erectile function is an important aspect of quality of life for men.…”

Section: Introductionmentioning

confidence: 99%

Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success

et al. 2009

View full text Add to dashboard Cite

The reliability of response to treatment is an important component of erectile dysfunction (ED) treatment. This study examined the reliability of tadalafil once daily (that is, successful attempts/total attempts) following initial successful intercourse. Data pooled from two randomized, double-blind, placebo-controlled trials of men with ED who received tadalafil 2.5 mg (N=96), tadalafil 5 mg (N=206) or placebo (N=148) once daily were analyzed to determine the first-attempt success rate and subsequent reliability of response. The first-attempt success rate (Sexual Encounter Profile question 3 (SEP3)) was significantly higher among men taking tadalafil 2.5 mg (45.7%) and 5 mg (55.2%) compared to placebo (28.5%; P<0.05 and P<0.001, respectively). Furthermore, following initial success, men taking tadalafil 5 mg had a significantly greater proportion of successful intercourse (SEP3) on subsequent attempts (85.9%, P<0.001) compared to men taking placebo (70.2%). Overall, men with ED taking tadalafil once daily experienced a high rate of reliability of efficacy.

show abstract

Vardenafil provides reliable efficacy over time in men with erectile dysfunction

Cited by 30 publications

References 18 publications

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction

Toward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction

A Review of Hypogonadism and Erectile Dysfunction Among HIV-Infected Men During the Pre- and Post-HAART Eras: Diagnosis, Pathogenesis, and Management

Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success

Contact Info

Product

Resources

About